

EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY

European Journal of Cardio-thoracic Surgery 33 (2008) 961-970

www.elsevier.com/locate/ejcts

Review

# No improvement in neurocognitive outcomes after off-pump versus on-pump coronary revascularisation: a meta-analysis

Silvana F. Marasco<sup>a,\*</sup>, Lisa N. Sharwood<sup>b</sup>, Michael J. Abramson<sup>c</sup>

<sup>a</sup> CJOB Cardiothoracic Department, The Alfred Hospital, Commercial Road, Prahran 3181, Victoria, Australia <sup>b</sup> Murdoch Children's Research Institute, Royal Children's Hospital, Flemington Road, Parkville 3045, Australia <sup>c</sup> Department of Epidemiology and Preventive Medicine, Monash University, Central & Eastern Clinical School, The Alfred Hospital, Melbourne 3004, Australia

Received 29 October 2007; received in revised form 6 March 2008; accepted 19 March 2008

## Summary

The popularity of off-pump (beating heart) coronary artery bypass grafting (CABG) was initially stimulated by numerous theoretical benefits including lower incidence of stroke and neurocognitive dysfunction. With a postoperative stroke rate of less than 1% for elective CABG, it has been very difficult to demonstrate any significant differences in this outcome between techniques. However, changes in neurocognitive function are more common in the postoperative setting and thus provide greater power for demonstrating improvement with changes in surgical technique. The aim of this meta-analysis was to assess whether there were significant differences in neurocognitive outcomes in patients after undergoing off-pump versus on-pump CABG. A database search for prospective randomised controlled trials of off-pump versus on-pump CABG in any language was conducted. Eight trials incorporating 892 patients fulfilled all the inclusion criteria for reporting of neurocognitive outcomes, and were able to be included in this meta-analysis. Sufficient data were available across the seven studies to combine results for five neurocognitive tests (Rey Auditory Verbal Learning, Grooved Pegboard, Trail A and B, and Digit Symbol). Overall there were no convincing differences in outcomes in neurocognitive testing between off-pump and on-pump CABG groups. The results of this meta-analysis show that there are no significant neurocognitive benefits when comparing off-pump versus on-pump CABG.

Crown Copyright 🕜 2008 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.

Keywords: Meta-analysis; Neurologic manifestations; Coronary artery bypass; Off-pump

## 1. Introduction

There has been intense debate regarding the benefits of off-pump coronary revascularisation in comparison to more traditional techniques using the cardiopulmonary bypass circuit and cardiac arrest. Off-pump surgery techniques maintain pulsatile flow, and avoid passing blood through a synthetic circuit and oxygenator, thus reducing activation of the coagulation and inflammatory cascades [1,2]. Further, the use of the cardiopulmonary bypass circuit has been associated with cerebral microemboli and could potentially be avoided by the use of off-pump techniques [3,4].

In addition, off-pump coronary revascularisation involves less handling of the often atheromatous ascending aorta. This reduces the incidence of microemboli that have been shown to occur at the time of application and particularly with release of the aortic cross-clamp or side-biting clamp [4].

Until recently, no systematic review was able to demonstrate stroke reduction with off-pump coronary

\* Corresponding author. Tel.: +61 3 9276 2000; fax: +61 3 9276 2317. *E-mail address:* s.marasco@alfred.org.au (S.F. Marasco).

revascularisation. However, a meta-analysis recently published by Sedrakyan and colleagues [5] was able to demonstrate a 50% relative risk reduction of stroke using off-pump techniques compared to on-pump coronary artery bypass graft (CABG) surgery. Because the incidence of stroke is very low following CABG (generally under 1%), it has been difficult to demonstrate a significant reduction in stroke incidence after off-pump surgery in individual trials [6]. For this reason, investigators have looked to more subtle neurological changes following surgery such as neurocognitive decline. However, even these results have varied widely between individual trials. No previous systematic review has specifically analysed the results of neurocognitive outcomes following off-pump versus onpump CABG. The purpose of this meta-analysis therefore was to assess these outcomes.

# 2. Methods

This meta-analysis was conducted using the recommendations made in the QUOROM statement as a guide [7].

<sup>1010-7940/\$ -</sup> see front matter. Crown Copyright © 2008 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved. doi:10.1016/j.ejcts.2008.03.022

## 2.1. Search strategy

All published prospective randomised controlled trials assessing neurocognitive outcomes after off-pump versus onpump coronary revascularisation were considered. Studies were compiled from systematic literature searches of databases including Cochrane (reviews and registry of controlled trials), Medline and PsycINFO for the last twenty years up until September 2007.

The search strategy included the terms 'off-pump coronary revascularisation', 'off-pump coronary artery bypass', 'randomised' controlled trial, 'controlled clinical trial' and combinations of 'neurocognitive outcomes', 'neurocognitive tests' and 'brain function'. All studies were then reviewed to determine if they had included neurocognitive outcomes as an endpoint. A search of other reviews of coronary revascularisation techniques was also conducted, checking reference lists of these articles also for further relevant studies. The search was also repeated at regular intervals during this systematic review to ensure any new publications were captured. The search strategy included all languages. The search was conducted by both the first and second authors who also reviewed the papers and culled the list according to the entry criteria of this search.

# 2.2. Inclusion and exclusion criteria

Prospective randomised trials comparing off-pump versus on-pump coronary artery revascularisation were included, whereby patients were randomly assigned to either off-pump or on-pump CABG. All patient populations were considered eligible. Neurocognitive testing as an endpoint in the study was a prerequisite. All language publications were considered eligible.

Exclusions were made where the trials were found to be not truly randomised, where brain function assessments were performed using magnetic resonance imaging or cerebral microemboli markers as opposed to neuropsychological testing. Also excluded were studies not conforming to the recommended 'consensus statement' on neurocognitive outcomes testing and reporting after cardiac surgery [8].

Where there was insufficient data reported on the neurocognitive tests to obtain means and standard deviations, the corresponding authors of those papers were contacted.

# 2.3. Data extraction

A standard neurocognitive test battery was used in the eight included studies, conforming to the consensus statement of neurocognitive testing after cardiac surgery [8]. Not all papers reported all tests, rather a selection of tests to assess each cognitive domain. However, some papers had data missing (e.g. baseline figures which were not published, or data which was represented graphically only), and all of these primary authors were contacted to request this information.

After completing the search strategy as outlined above, the relevant data were extracted from the identified papers by two reviewers working together (SFM, LNS).

#### 2.4. Endpoints

The endpoints used in this meta-analysis were short term (less than or equal to 3 months) and long-term (greater or equal to 6 months) neurocognitive performance of cardiac surgery patients, after undergoing off-pump or on-pump CABG. Where authors had tested patients at two time points within the first three postoperative months, the later time point was used.

# 2.5. Statistical analysis

The outcomes were analysed as continuous variables and the mean and standard deviations were available for all data used. The weighted mean difference was calculated for each outcome. The meta-analysis was performed using Review Manager (RevMan) Version 4.2 for Windows. (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2003). Heterogeneity was explored by calculating the  $l^2$ statistic to quantify the degree of heterogeneity across the trials that could not be attributed to chance alone. For each analysis, the fixed effect (precision weighted) or random effects (Der-Simonian and Laird) model was chosen depending on the degree of heterogeneity. Statistical significance was defined as two-sided p < 0.05. Publication bias was assessed using funnel plots.

Post hoc sample size analysis showed that there were sufficient numbers to detect a 6% difference in test results (averaged across all five neurocognitive tests) with a power of 0.8 and type II error of <0.05.

# 3. Results

Eighty-three studies were identified by the initial literature search, which included a review of all references of other systematic review articles comparing off-pump to on-pump surgery (although with different endpoints). The abstracts or full articles of all these studies were reviewed and 59 studies were able to be excluded because they were either case studies, retrospective reviews, compared off-pump surgery to percutaneous interventions, or were review articles.

Twenty-four studies were initially identified for possible inclusion in the meta-analysis [9–32]. Corresponding authors were contacted where further clarification of study design (randomisation techniques, or duplication of data) were required, and where there was insufficient reporting and further data was required for inclusion into the meta-analysis. Of the 10 authors contacted, seven replied and two were able to forward further data to enable inclusion in the meta-analysis [25,31]. Of the 24 studies initially identified for possible inclusion in the meta-analysis, 16 were rejected and are listed in Table 1 [9–24]. The primary endpoints in those trials and the reasons for exclusion are also listed.

The eight studies which were included, along with the study design are outlined in Table 2 [25–32]. The study population demographics are outlined below in Table 3. Analysis by funnel plot showed no significant publication bias.

The eight trials in this meta-analysis included 892 patients. Five neurocognitive tests were able to be analysed,

Table 1	
Excluded	studies

No.	Year of publication	Author	Randomised study	No. of patients	Primary endpoints	Reason for exclusion from current meta-analysis
1	2000	Westaby et al. [9]	No	100	$S\text{-}100\beta$ levels and neuropsychological measures	No off-pump group and insufficient reporting of neurocognitive measures
2	2000	Diegeler et al. [10]	Yes	40	Transcranial Doppler to assess HITS, S-100 $\beta$ levels and neuro-psychological testing	Standard neurocognitive tests not used
3	2000	Lloyd et al. [11]	Yes	60	Neuropsychological testing and S-100 $\beta$ levels	Insufficient reporting of neurocognitive measures
4	2003	Lund et al. [12]	Yes	52	Transcranial Doppler to assess HITS, cerebral MRI and neuro-psychological testing	Data contained in later publication
5	2003	Schmitz et al. [13]	No	251	Neurocognitive testing	Non randomised
6	2003	Keizer et al. [14]	Yes	81	Neurocognitive testing	Neurocognitive testing did not follow consensus statement
7	2004	Van Dijk et al. [15]	Yes	281	Neurocognitive testing	Contained data on previous published results
8	2005	Ascione et al. [16]	Yes	20	Fluorescein angiography and transcranial Doppler to assess HITS	No neurocognitive testing
9	2005	Stroobant et al. [17]	No	50	Transcranial Doppler to assess HITS and cerebral blood flow velocity	Non randomised
10	2005	Kobayashi et al. [18]	Yes	167	3-Year cardiac events. Secondary endpoints of completeness of revascularisation, early clinical outcomes and neurocognitive function	\$100 and neuron-specific enolase reported but no neurocognitive testing
11	2005	Diephius et al. [19]	Yes	175	Jugular bulb desaturation	No neurocognitive testing
12	2006	Jensen et al. [20]	Yes	120	Neuropsychological testing	Insufficient reporting of neurocognitive measures (no means or standard deviations)
13	2006	Chernov et al. [21]	No	65	Brain SPECT scanning, neurocognitive testing	Non randomised
14	2006	Bonacchi et al. [22]	Yes	42	S-100 $\beta$ levels and neuron-specific enolase	No neurocognitive testing
15	2007	Biancari et al. [23]	No	1016	Stroke score risk	Non randomised
16	2007	Motallebzadeh et al. [24]	Yes	212	Neurocognitive testing and transcranial Doppler to assess HITS	Insufficient reporting of neurocognitive measures

SPECT: single photon emission computed tomographic scan; MRI: magnetic resonance imaging; HITS: high-intensity transient signals. Trials excluded from meta-analysis.

as there were enough studies which included these particular tests. The tests and the respective cognitive domain assessed were: Rey Auditory Verbal Learning (verbal memory), Grooved Pegboard (motor capacity), Trail A and B (divided attention and executive function), and the WAIS III Digit Symbol test (information processing). The other tests were not consistently used by enough of the studies to have sufficient data to combine. Results were available at baseline, less than 3 months postoperatively and between 6 and 12 months postoperatively for these three cognitive domains.

The results of the Rey Auditory Verbal Learning test (Fig. 1) show no significant differences between those patients who underwent off-pump or on-pump coronary revascularisation either at baseline, in the first 3 months postoperatively or between 6 and 12 months postoperatively. There was also no significant change between baseline and the two postoperative time points in either group. No significant heterogeneity was noted at baseline or at the less than 3 months testing. However, there was significant heterogeneity noted at the late neurocognitive testing (6–12 months) with an  $l^2$  of 79.8% (p = 0.002). Re-analysis using a random effects model did not alter the lack of effect of treatment seen with the fixed effects model.

The results of the Grooved Pegboard test showed no significant differences between off-pump and on-pump CAGS at baseline or at either postoperative time point (Fig. 2). Significant heterogeneity was noted in the 3-month time

point with an  $l^2$  of 68.5% (p = 0.01) and again re-analysis using a random effects model did not alter the effect seen.

Meta-analysis of Trail A test data is shown in Fig. 3. In this particular neurocognitive test, significant improvements in function were seen in the off-pump groups at both the early (z = 2.36; p = 0.02) and late (z = 4.06; p < 0.0001) time periods. No significant heterogeneity was seen at either time point. The baseline assessment showed no significant differences between groups and no significant heterogeneity.

In contrast, the Trail B test, which assesses a similar domain to the Trail A test, did not show any significant differences between groups at any time point (Fig. 4). Significant heterogeneity was noted at the early post-operative time point  $l^2$  of 70% (p = 0.003), but not at the other time points. Re-analysis at the early postoperative time point with a random effects model did not show any significant differences between groups.

The final test was the Digit Symbol which showed significant heterogeneity with a fixed effects model, thus a random effects model is presented (Fig. 5). Significant heterogeneity remains at the early postoperative time point ( $l^2$  70.1%; p = 0.005), but not the other time points. No differences between groups were noted in the test results at any time point. Interestingly, after removal of the study by Lee et al. [28], which is a significant outlier, the pooled results showed no significant heterogeneity, and significant differences in favour of the off-pump group at both the baseline (z = 2.42; p = 0.02) and at the early postoperative time point (z = 2.56; p = 0.01) [25].

Table 2	
Included	studies

No.	Year of publication	Author	No. of patients	Primary endpoints	Randomisation and allocation method	Allocation concealed <sup>a</sup>	Intention to treat analysis?	Loss to follow up (no. of patients/% of group) <sup>b</sup>
1	2001	Baker et al. [25]	26	Troponin T and neuropsychological testing	Not described	Not clear	No crossover	4 (33%) off-pump
				-				4 (29%) on-pump
2	2002	Zamvar et al. [26]	60	Neurocognitive testing	Computer generated/ sealed envelope	Yes	No crossover	None
3	2002	Van Dijk et al. [27]	281	Neurocognitive testing	Computerised block randomisation/telephone	Not clear	Yes (15 crossovers)	12 (8%) off-pump
								17 (12%) on-pump
4	2003	Lee et al. [28]	60	Neurocognitive testing, whole brain SPECT, transcranial Doppler to assess HITS	Sealed envelope	Yes	No crossover	3 (10%) off-pump
								4 (13%) on-pump
5	2005	Lund et al. [29]	120	Neurocognitive testing and cerebral MRI	Block randomisation	Yes	Yes (7 crossovers)	6 (10%) off-pump
								8 (13%) on-pump
6	2006	Al-Ruzzeh et al. [30]	164	Angiographic graft patency and neurocognitive function	Computer generated	Yes	No crossover	11 (13%) off-pump
				5				12 (14%) on-pump
7	2006	Ernest et al. [31]	107	Neurocognitive testing	Computer generated/ sealed envelope	Yes	Yes (1 crossover only)	14 (23%) off-pump
								14 (30%) on-pump
8	2006	Vedin et al. [32]	70	Neurocognitive testing	Not described	Not clear	Yes (3 crossovers)	3 (9%) off-pump 5 (14%) on-pump

Trials included in meta-analysis. <sup>a</sup> Blinded to neuropsychologist examiner. <sup>b</sup> loss to follow up at latest testing period.

## Table 3 Demographics of patients in included studies

	Treatment group	Author and reference number							
		Baker et al. [25]	Van Dijk et al. [26]	Zamvar et al. [27]	Lee et al. [28]	Lund et al. [29]	Al Ruzzeh et al. [30]	Ernest et al. [31]	Vedin et al. [32]
		Year of publi	cation						
		2001	2002	2002	2003	2005	2006	2006	2007
		Number of pa	atients						
		N = 26	<i>N</i> = 281	<i>N</i> = 60	<i>N</i> = 60	<i>N</i> = 120	<i>N</i> = 168	<i>N</i> = 107	<i>N</i> = 70
Age (years) (mean $\pm$ SD)	Off-pump	$\textbf{61.7} \pm \textbf{11.7}$	$\textbf{61.7} \pm \textbf{9.2}$	$\textbf{63.5} \pm \textbf{9.1}$	$\textbf{65.5} \pm \textbf{9.6}$	$\textbf{64.8} \pm \textbf{7.8}$	$\textbf{63.1}\pm\textbf{11}$	$\textbf{63.2} \pm \textbf{9.0}$	$\textbf{65.0} \pm \textbf{9.1}$
	On-pump	$\textbf{65.9} \pm \textbf{8.3}$	$\textbf{60.8} \pm \textbf{8.8}$	$\textbf{61.6} \pm \textbf{10}$	$\textbf{66} \pm \textbf{11.2}$	$\textbf{65.2} \pm \textbf{8.4}$	$\textbf{63.1} \pm \textbf{9.6}$	$\textbf{63.7} \pm \textbf{10.7}$	$\textbf{65.0} \pm \textbf{9.1}$
Gender (male %)	Off-pump On-pump	92 71	66 71	83 90	80 73	85 72	83 84	78 81	78 84
Diabetes (%)	Off-pump On-pump	11 30	9 17	NR NR	20 37	NR NR	24 21	27 31	18 19
Hypertension (%)	Off-pump On-pump	56 70	40 44	NR NR	70 87	42 43	62 55	79 79	52 46
Previous stroke (%)	Off-pump On-pump	0 0	4 3	Excluded Excluded	7 3	8.3 6.6	NR NR	7.1 3.6	3 0
Education (years)	Off-pump On-pump	NR NR	NR NR	NR NR	11.7 13.0	9.9 8.3	NR NR	11.0 11.9	13.3 12.7

NR: not reported.

Demographics of patients in included trials.

Review:	Off pump vs on pump (Marasco)
Comparison:	01 Off pump vs on pump coronary revascularisation
Outcome:	01 Rey Auditory Verbal Learning

Study or sub-category	N	Off pump Mean (SD)	N	On pump Mean (SD)	WMD (fixed) 95% Cl	Weight %	WMD (fixed) 95% Cl
01 Baseline							
Van Dijk (2002)	142	-36.00(8.97)	139	-36.00(8.58)		49.22	0.00 [-2.05, 2.05]
Zamvar (2002)	30	-36.00(8.83)	30	-35.20(8.99)		10.19	-0.80 [-5.31, 3.71]
Lee (2003)	29	-36.10(13.10)	29	-39.20(16.10)		3.63	3.10 [-4.45, 10.65]
Lund (2005)	60	-33.60(8.90)	60	-35.70(7.90)		22.86	2.10 [-0.91, 5.11]
Ernest (2006)	61	-37.02(9.63)	46	-37.85(10.30)		14.10	0.83 [-3.00, 4.66]
Subtotal (95% CI)	322		304		+	100.00	0.63 [-0.81, 2.07]
Test for heterogeneity: Chi	<sup>2</sup> = 2.09, df = 4 (F	= 0.72), I <sup>2</sup> = 0%					
Test for overall effect: Z =	0.86 (P = 0.39)	2010-0000000 ••• 0 - 2010010101000					
02 Early neurocognitive sta	atus (less than 3)	months)					
Van Dijk (2002)	128	-38.00(9.75)	120	-37.00(10.92)		41.89	-1.00 [-3.58, 1.58]
Zamvar (2002)	30	-38,60(9,20)	30	-36,53(8,00)		14.68	-2.07 [-6.43, 2.29]
Lee (2003)	29	-42.20(13.60)	29	-44.40(15.20)		5.07	2.20 [-5.22, 9.62]
Lund (2005)	54	-37,90(9,00)	52	-41.20(8.70)		24.61	3.30 [-0.07, 6.67]
Ernest (2006)	44	-40,07(9,66)	31	-37,48(9,91)		13.75	-2.59 (-7.10, 1.92)
Subtotal (95% CI)	285		262		-	100.00	-0.16 (-1.83, 1.52)
Test for heterogeneity: Chi	$^{2} = 6.70$ , df = 4 (F	= 0.15), l <sup>2</sup> = 40.3%			T		
Test for overall effect: Z =	0.18 (P = 0.86)						
03 Late neurocognitive sta	tus (greater than	6 months)					
Van Diik (2002)	130	-41.00(10.14)	122	-37.00(9.75)		54.36	-4.00 [-6.461.54]
Lee (2003)	27	-42.70(12.00)	26	-43.70(14.80)		- 6.20	1.00 [-6.27, 8.27]
Lund (2005)	54	-37.40(10.70)	52	-41.80(7.90)		- 25.71	4.40 [0.83, 7.97]
Ernest (2006)	47	-40.59(12.06)	32	-40.25(10.00)		13.72	-0.34 [-5.23, 4.55]
Subtotal (95% CI)	258		232		-	100.00	-1.03 [-2.84, 0.78]
Test for heterogeneity: Chi	2 = 14.87, df = 3 (	P = 0.002),   <sup>2</sup> = 79.8%					
Test for overall effect: Z =	1.11 (P = 0.27)						
					-10 -5 0 5	10	

Favours off pump Favours on pump

Fig. 1. Meta-analysis of Rey Auditory Verbal Learning.

Of Baseline   Of Baseline   0.1 Mathety   0.1 Mathety   0.1 Mathety     Van Dijk (2002)   142   106.00 (19.11)   139   104.00 (19.50)   60.14   2.00 [-2.52, 6.52]     Zamvar (2002)   30   99.93 (48.52)   30   91.20 (38.05)   2.52   8.73 [-13.33, 30.79]     Lue (2003)   29   97.80 (30.70)   29   95.80 (46.90)   2.95   1.00 [-19.00, 21.40]     Lund (2005)   60   84.50 (19.30)   60   81.30 (16.90)   29.10   3.20 (-3.29, 9.69)     Emest (2006)   61   91.30 (20.11)   46   99.76 (49.65)   5.30   -8.46 [-23.67, 6.75]     Subtotal (85% Cl)   322   304   100.00   1.33 [-1.57, 5.44]   100.00     Test for heterogenetity: Ch <sup>2</sup> = 2.31, df = 4 (P = 0.68), P = 0.28)   102.00 (14.04)   -   57.47   -2.00 [-6.10, 2.10]     Zamvar (2002)   128   100.00 (18.72)   120   102.00 (14.04)   -   10.44   -16.17 [-25.79, -6.55]     Lue (2003)   29 3 92.30 (29.10)   29   105.80 (67.10)   1.36   -1.35 [-4.0.12, 1.3.12]     Lue (2005)   54   82.40 (18.90)   52   7	2, 6.52)	2 00 1-2 52				Mean (SD)	N	Mean (SD)	N	or sub-category
Of Baseline   Van Dijk (2002)   142   106.00(19.11)   139   104.00(19.50)   60.14   2.00   [-2.52, 6.52]     Zamvar (2002)   30   99.93(48.52)   30   91.20(38.05)   2.95   1.00   [-1.9.40, 21.40]     Lee (2003)   29   97.80(30.70)   29   96.80(46.90)   2.95   1.00   [-1.9.40, 21.40]     Ernest (2005)   61   91.30(20.11)   46   99.76(49.65)   5.30   -8.46   [-23.67, 6.75]     Subtoal (55% C)   322   304   300   100.00   1.93   [-1.57, 5.44]     Test for heterogeneity: Chi" = 2.31, df = 4 (P = 0.68), P = 0%   304   57.47   -2.00   [-6.10, 2.10]     Zamvar (2002)   30   95.73(14.10)   30   111.90(22.90)   10.44   -16.17   [-2.27, 1.08]     Lee (2003)   29   92.30(29.10)   29   105.80(67.10)   1.36   -13.50   [-40.12, 13.12]     Lee (2005)   54   82.40(18.90)   52   78.10(15.60)   22.29   4.30   [-2.29, 1.0.8]     Subtoal (95% C)   285   262   100.00   -2.05   [-5.16, 1.06]   10	2, 6.52)	2 00 1-2 52								
Variation (2002)   142   104 <td>2, 5.32]</td> <td></td> <td>CO 14 0 00</td> <td>(0.14</td> <td>L</td> <td>104 00410 501</td> <td>100</td> <td>100 00010 111</td> <td>140</td> <td>1 Baseline</td>	2, 5.32]		CO 14 0 00	(0.14	L	104 00410 501	100	100 00010 111	140	1 Baseline
$\begin{array}{c c c c c c c c c c c c c c c c c c c $		0.00 ( 2:02,	50.14 2.00	60.14	<b>—</b>	104.00(19.50)	139	106.00(19.11)	142	Vali Dijk (2002)
Lee (2003) 29 97.60(30.70) 29 96.6(49.65) Ernest (2005) 60 84.50(19.30) 60 81.30(16.50) Ernest (2005) 61 91.30(20.11) 46 99.76(49.65) Subtotal (95% CI) 322 304 Test for overall effect: Z = 1.08 (P = 0.68), P = 0% Test for overall effect: Z = 1.08 (P = 0.68), P = 0% Test for overall effect: Z = 1.08 (P = 0.28) D2 Early neurocognitive status (less than 3 months) Van Dijk (2002) 128 100.00(18.72) 120 102.00(14.04) Zamvar (2002) 30 95.73(14.10) 30 111.90(22.90) Ernest (2005) 54 82.40(18.90) 52 78.10(15.60) Ernest (2005) 54 82.40(18.90) 52 78.10(15.60) Ernest (2005) 44 87.53(21.30) 31 87.38(24.61) Subtotal (95% CI) 285 262 Test for heterogeneity: Chi <sup>p</sup> = 12.71, df = 4 (P = 0.01), P = 68.5% Test for overall effect: Z = 1.29 (P = 0.01), P = 68.5% Test for overall effect: Z = 1.29 (P = 0.01), P = 68.5% Test for overall effect: Z = 1.29 (P = 0.01), P = 68.5% Test for overall effect: Z = 1.29 (P = 0.01), P = 68.5% Test for overall effect: Z = 1.29 (P = 0.01), P = 68.5% Test for overall effect: Z = 1.29 (P = 0.01), P = 68.5% Test for overall effect: Z = 1.29 (P = 0.01), P = 68.5% Test for overall effect: Z = 1.29 (P = 0.01), P = 68.5% Test for overall effect: Z = 1.29 (P = 0.01), P = 68.5% Test for overall effect: Z = 1.29 (P = 0.01), P = 68.5% Test for overall effect: Z = 1.29 (P = 0.01), P = 68.5% Test for overall effect: Z = 1.40 (P = 0.01), P = 68.5% Test for overall effect: Z = 1.40 (P = 0.01), P = 68.5% Test for overall effect: Z = 1.40 (P = 0.01), P = 68.5% Test for overall effect: Z = 1.40 (P = 0.01), P = 68.23 Test for heterogeneity: Chi <sup>p</sup> = 1.271, 0.64 (= .278, 0.00 (= .266, 2.62) Subtotal (95% CI) 2.28 232 Test for heterogeneity: Chi <sup>p</sup> = 1.40, df = 3 (P = 0.70), P = 0% Test for overall effect: Z = 1.45 (P = 0.05), P = 0% Test for overall effect: Z = 1.45 (P = 0.05), P = 0% Test for overall effect: Z = 1.45 (P = 0.07), P = 0% Test for overall effect: Z = 1.45 (P = 0.07), P = 0% Test for overall effect: Z = 1.45 (P = 0.07), P = 0% Test for overall effect: Z = 1.45 (P = 0.	40, 00.75	8.73 (-13.33,	2.52 8.73			91.20(38.05)	30	99.93(48.52)	30	Zamvar (2002)
Lund (2005) 60 84.50 (125.30) 60 84.50 (125.30) 60 81.76 (49.65) Ernest (2005) 61 91.30 (20.11) 46 99.76 (49.65) Subtotal (95% C1) 322 304 100.00 1.93 [-1.57, 5.44] 100.00 -2.05 [-5.16, 10.8] 100.00 [-7.34, 1.34] 100.00 [-7.34, 1.34] 100.00 [-7.34, 1.34] 100.00 [-7.34, 1.34] 100.00 [-1.40, 14.00] 100.00 [-2.41 [-5.67, 0.84] 100.00 [-2.41 [-5.67, 0.84] 100.00 [-2.41 [-5.67, 0.84]	40, 21.40	1.00 [-19.40,	2.95 1.00	- 2.95		96.80(46.90)	29	97.80(30.70)	29	Lee (2003)
Lines (2000)   6.1   91.30(20.11)   46   92.76(45.65)     Subtol (55% Cl)   322   304     Test for heterogeneity: Ch <sup>2</sup> = 2.31, df = 4 (P = 0.68), P = 0%   100.00   1.93 (-1.57, 5.44)     Test for heterogeneity: Ch <sup>2</sup> = 2.31, df = 4 (P = 0.68), P = 0%   100.00 (18.72)   120     Yan Dijk (2002)   128   100.00 (18.72)   120   102.00(14.04)     Zamvar (2002)   30   95.73(14.10)   30   111.90(22.90)     Zamvar (2002)   30   95.73(14.10)   30   111.90(22.90)     Lee (2003)   29   92.30(29.10)   29   105.80(67.10)   1.36   -13.50   1-40.12, 13.121     Lund (2005)   54   82.40(18.90)   52   78.10(15.60)   22.29   4.30   (-2.29, 10.08)     Ernest (2003)   285   262   100.00   -2.05 [-5.16, 1.06]   100.00   -2.05 [-5.16, 1.06]     Subtotal (55% Cl)   285   262   100.00   -2.05 [-5.16, 1.06]   100.00   -2.05 [-5.16, 1.06]     Iest for overall effect: Z = 1.29 (P = 0.20)   13   103   9.00(17.55)   122   102.00(17.55)   56.31   -3.00 [-7.34, 1.34]   100.0	9, 9.69	3.20 [-3.29, 1	5 20 -0.46	29.10		81.30(16.90)	60	84.50(19.30)	60	Euna (2005)
Source (15/8 G)   3/4   100.00   1.33   1.	07, 0.75J	-0.40 [-23.07,	3.30 -0.40	3.30		33.76(43.63)	204	91.30(20.11)	222	Enlest (2006)
Lest on interlogeneity. Chr = 2.51, di = 4 (P = 0.00), F = 0.8     12 Early neurocognitive status (less than 3 months)     Van Dijk (2002)   128   100.00 (18.72)   120   102.00 (14.04)     2 Zamvar (2002)   30   95.73 (14.10)   30   111.90 (22.90)     Lee (2003)   29   2.30 (29.10)   29   105.80 (67.10)     Lund (2005)   54   82.40 (18.90)   52   78.10 (15.60)     Ernest (2006)   44   97.53 (21.30)   31   87.38 (24.61)     Subtotal (55% Cf)   285   262     Fest for overall effect: Z = 1.29 (P = 0.20)   102.00 (17.55)   122   102.00 (17.55)     30 Late neurocognitive status (greater than 6 months)   Van Dijk (2002)   30   99.00 (17.55)   122   102.00 (17.55)     Van Dijk (2002)   130   99.00 (17.55)   122   102.00 (17.55)   56.31   -3.00   [-7.34, 1.34]     Lee (2003)   27   91.50 (26.00)   26   91.50 (26.00)   54.00   0.00   [-14.00, 14.00]     Lund (2005)   54   78.80 (16.80)   52   78.80 (16.10)   56.31   -3.00   [-7.34, 1.34]   100.00   -2.41	7, 5.44)	1.33 [-1.37,	100.00 1.93	100.00			304	0 - 0 69) 12 - 0%	-231 df - 4 (5	lest for beterogeneity: Chiz-
2)2 Early neurocognitive status (less than 3 months)     Van Dijk (2002)   128   100.00 (18.72)   120   102.00 (14.04)     Zamvar (2002)   30   95.73 (14.10)   30   111.90 (22.90)     Lee (2003)   29   2.30 (29.10)   29   105.80 (67.10)     Lund (2005)   54   82.40 (18.90)   52   78.10 (15.60)     Ernest (2006)   44   87.53 (21.30)   31   87.38 (24.61)   8.43   0.15   [-10.56, 10.86]     Subtotal (95% CI)   285   262   100.00   -2.05   [-5.16, 1.06]     Subtotal (95% CI)   285   262   100.00   -2.05   [-5.16, 1.06]     Subtotal (95% CI)   285   262   100.00   -2.05   [-5.16, 1.06]     Subtotal (95% CI)   285   262   100.00   -2.05   [-5.16, 1.06]     Subtotal (95% CI)   28   28   202.00 (17.55)   122   102.00 (17.55)   100.00   -2.05   [-5.16, 1.06]     Subtotal (2005)   13   99.00 (17.55)   122   102.00 (17.55)   56.31   -3.00   [-7.34, 1.34]     Lee (2003)   27								0.00),1 - 0.8	.08 (P = 0.28)	lest for overall effect: Z = 1.
Van Dijk (2002)   128   100.00 (18.72)   120   102.00 (14.04)   Image: constraint of the constra								months)	us (less than 3	2 Early neurocognitive statu
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	0, 2.10]	-2.00 (-6.10,	57.47 -2.00	57.47		102.00(14.04)	120	100.00(18.72)	128	Van Dijk (2002)
Lee (2003) 29 92.30 (29.10) 29 105.80 (67.10) - 1.36 -3.50 [-40.12, 13.12] Lund (2005) 54 82.40 (18.90) 52 78.10 (15.60) 22.29 4.30 [-2.29, 10.89] Ernest (2005) 44 97.53 (21.30) 31 87.38 (24.61) - 8.43 0.15 [-10.56, 10.86] Subtotic (95% Cl) 285 262 100.00 -2.05 [-5.16, 1.06] rest for heterogeneity: Ch <sup>2</sup> = 1.29 (P = 0.20) 33 Lete neurocognitive status (greater than 6 months) Van Dijk (2002) 130 99.00 (17.55) 122 102.00 (17.55) - 56.31 -3.00 [-7.34, 1.34] Lee (2003) 27 91.50 (26.00) 26 91.50 (26.00) - 5.40 0.00 [-14.00, 14.00] Lund (2005) 54 78.80 (16.80) 52 78.80 (16.10) - 5.40 0.00 [-14.00, 14.00] Lund (2005) 47 81.84 (16.23) 32 88.23 (24.50) - 11.31 -6.39 [-16.06, 3.28] Subtotic (95% Cl) 258 232 100.00 (-2.41 [-5.67, 0.84] lest for heterogeneity: Ch <sup>2</sup> = 1.40, (ft = 3 (P = 0.70), l <sup>2</sup> = 0% lest for heterogeneity: Ch <sup>2</sup> = 1.40, (ft = 3 (P = 0.70), l <sup>2</sup> = 0% lest for heterogeneity: Ch <sup>2</sup> = 1.40, (ft = 3 (P = 0.70), l <sup>2</sup> = 0% lest for heterogeneity: Ch <sup>2</sup> = 1.40, (ft = 3 (P = 0.70), l <sup>2</sup> = 0% lest for heterogeneity: Ch <sup>2</sup> = 1.40, (ft = 3 (P = 0.70), l <sup>2</sup> = 0% lest for heterogeneity: Ch <sup>2</sup> = 1.40, (ft = 3 (P = 0.70), l <sup>2</sup> = 0% lest for heterogeneity: Ch <sup>2</sup> = 1.40, (ft = 3 (P = 0.70), l <sup>2</sup> = 0% lest for heterogeneity: Ch <sup>2</sup> = 1.40, (ft = 3 (P = 0.70), l <sup>2</sup> = 0% lest for heterogeneity: Ch <sup>2</sup> = 1.40, (ft = 3 (P = 0.70), l <sup>2</sup> = 0% lest for heterogeneity: Ch <sup>2</sup> = 1.40, (ft = 3 (P = 0.70), l <sup>2</sup> = 0% lest for heterogeneity: Ch <sup>2</sup> = 1.40, (ft = 3 (P = 0.70), l <sup>2</sup> = 0% lest for heterogeneity: Ch <sup>2</sup> = 1.40, (ft = 3 (P = 0.70), l <sup>2</sup> = 0% lest for heterogeneity: Ch <sup>2</sup> = 1.45, (ft = 0.15)	79, -6.55	-16.17 [-25.79,	10.44 -16.17	10.44		111.90(22.90)	30	95.73(14.10)	30	Zamvar (2002)
Lund (2005) 54 82.40(18.90) 52 78.10(15.60) 22.29 4.30 [-2.29, 10.89] Ernest (2005) 44 97.53(21.30) 31 87.38(24.61) 8.43 0.15 [-10.56, 10.86] Subtotal (55% Cl) 285 262 100.00 -2.05 [-5.16, 1.06] Eest for heterogeneity: Chi <sup>2</sup> = 12.71, df = 4 (P = 0.01), l <sup>2</sup> = 68.5% Fest for overall effect: Z = 1.29 (P = 0.20) 33 Late neurocognitive status (greater than 6 months) Van Dijk (2002) 130 99.00(17.55) 122 102.00(17.55) 56.31 -3.00 [-7.34, 1.34] Lee (2003) 27 91.50(26.00) 26 91.50(26.00) 52 78.80(16.10) 52 78.80(16.10) 52 78.80(16.10) 52 78.80(16.10) 52 88.23(24.50) 54 78.90(16.23) 32 88.23(24.50) 54 11.31 -6.39 [-15.06, 3.28] Subtotal (95% Cl) 258 232 100.00 -2.41 [-5.67, 0.84] Fest for overall effect: Z = 1.45 (P = 0.70), l <sup>2</sup> = 0% Fest for overall effect: Z = 1.45 (P = 0.70), l <sup>2</sup> = 0%	12, 13.12	-13.50 [-40.12,	1.36 -13.50	1.36	·	105.80(67.10)	29	92.30(29.10)	29	Lee (2003)
Ernest (2005) 44 87.53 (21.30) 31 87.38 (24.61) Subtatel (95% CI) 285 262 iest for heterogeneity: Ch <sup>2</sup> = 12.71, df = 4 (P = 0.01), l <sup>2</sup> = 68.5% iest for overall effect: Z = 1.29 (P = 0.20) 31 Lete neurocognitive status (greater than 6 months) Van Dijk (2002) 130 99.00 (17.55) 122 102.00 (17.55) Lee (2003) 27 91.50 (26.00) 26 91.50 (26.00) Lund (2005) 54 78.80 (16.80) 52 78.80 (16.10) Ernest (2006) 47 81.84 (16.23) 32 88.23 (24.50) Lete (2005) 47 81.84 (16.23) 32 88.23 (24.50) Lete (2006) 47 81.84 (16.23) 32 88.23 (24.50) Lete (2007) 258 232 iest for heterogeneity: Ch <sup>2</sup> = 1.40, df = 3 (P = 0.70), l <sup>2</sup> = 0% lete for overall effect: Z = 1.45 (P = 0.15).	9, 10.89]	4.30 [-2.29,	22.29 4.30	22.29		78.10(15.60)	52	82.40(18.90)	54	Lund (2005)
Subtoted (95% C) 285 262 100.00 -2.05 [-5.16, 1.06] 'est for heterogeneity: Ch <sup>2</sup> = 1271, df = 4 (P = 0.01), P = 68.5% 'est for overall effect: Z = 1.28 (P = 0.20) 'I3 Late neurocognitive status (greater than 6 months) Van Dijk (2002) 130 99.00 (17.55) 122 102.00 (17.55) Lee (2003) 27 91.50 (26.00) 26 91.50 (26.00) Lund (2005) 54 78.90 (16.00) 52 78.90 (16.10) Ernest (2006) 47 81.84 (16.23) 32 88.23 (24.50) 	56, 10.86	0.15 [-10.56,	8.43 0.15	8.43	-+-	87.38(24.61)	31	87.53(21.30)	44	Ernest (2006)
Test for heterogeneity: Ch <sup>2</sup> = 12.71, df = 4 (P = 0.01), P = 68.5% est for overall effect: Z = 1.29 (P = 0.20) 33 Lete neurocognitive status (greater than 6 months) Van Dijk (2002) 130 99.00 (17.55) 122 102.00 (17.55) Lee (2003) 27 91.50 (26.00) 26 91.50 (26.00) Lund (2005) 54 78.80 (16.60) 52 78.80 (16.10) Ernest (2006) 47 81.84 (16.23) 32 88.23 (24.50) Subtoat (95% Cl) 258 232 est for heterogeneity: Ch <sup>2</sup> = 1.45 (P = 0.70), P = 0% est for verall effect: Z = 1.45 (P = 0.70), P = 0%	6, 1.06]	-2.05 [-5.16,	100.00 -2.05	100.00	4		262		285	Subtotal (95% CI)
31 Late neurocognitive status (greater than 6 months)     Van Dijk (2002)   130   99.00 (17.55)   122   102.00 (17.55)   56.31   -3.00   [-7.34, 1.34]     Lee (2003)   27   91.50 (26.00)    5.40   0.00   [-14.00, 14.00]     Lund (2005)   54   78.80 (16.80)   52   78.80 (16.10)    26.98   0.00   [-6.26, 6.26]     Ernest (2006)   47   91.84 (16.23)   32   88.23 (24.50)    11.31   -6.39   [-16.06, 3.28]     Jubtotal (95% Cf)   258   232    100.00   -2.41   [-5.67, 0.84]     est for heterogeneity: Chi <sup>2</sup> = 1.45 (f = 0.70), H <sup>2</sup> = 0%   est for overall effect: Z = 1.45 (f = 0.15)     100.00   -2.41   [-5.67, 0.84]								(P = 0.01), l <sup>2</sup> = 68.5%	= 12.71, df = 4 ( .29 (P = 0.20)	est for heterogeneity: Chi <sup>2</sup> = est for overall effect: Z = 1
Van Dijk (2002)   130   99.00 (17.55)   122   102.00 (17.55)   56.31   -3.00   [-7.34, 1.34]     Lee (2003)   27   91.50 (26.00)   26   91.50 (26.00)    5.40   0.00   [-4.00, 14.00]     Lund (2005)   54   78.80 (16.80)   52   78.80 (16.10)    26.98   0.00   [-6.26, 6.26]     Ernest (2006)   47   81.84 (16.23)   32   88.23 (24.50)    11.31   -6.39   [-16.06, 3.28]     Subtotal (95% Cl)   258   232    100.00   -2.41   [-5.67, 0.84]     lest for heterogeneity: Chi <sup>2</sup> = 1.45 (0° = 0.70), H = 0%   isst for overall effect: Z = 1.45 (0° = 0.15) </td <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>6 months)</td> <td>is (greater than</td> <td>3 Late neurocognitive statu</td>								6 months)	is (greater than	3 Late neurocognitive statu
Lee (2003) 27 91.50 (26.00) 26 91.50 (26.00) - 5.40 0.00 [-14.00, 14.00] Lund (2005) 54 78.80 (16.80) 52 78.80 (16.10) 26.98 0.00 [-6.26, 6.26] Ernest (2006) 47 91.84 (16.23) 32 88.23 (24.50) - 11.31 -6.39 [-16.06, 3.28] Subtotal (95% Cl) 258 232 100.00 -2.41 [-5.67, 0.84] est for verall effect. Z = 1.45 (P = 0.70), P = 0% est for verall effect. Z = 1.45 (P = 0.15)	4, 1.34)	-3.00 [-7.34,	56.31 -3.00	56.31		102.00(17.55)	122	99.00(17.55)	130	Van Dijk (2002)
Lund (2005) 54 78.80 (16.80) 52 78.80 (16.10) Ernest (2005) 47 81.84 (16.23) 32 88.23 (24.50) Subtotal (95% CI) 258 232 est for heterogeneity: Chi <sup>2</sup> = 1.40, df = 3 (P = 0.70), I <sup>2</sup> = 0% 'est for heterogeneity: Chi <sup>2</sup> = 1.40, df = 3 (P = 0.70), I <sup>2</sup> = 0% 'est for heterogeneity: Chi <sup>2</sup> = 1.45 (P = 0.15)	00, 14.00	0.00 [-14.00,	5.40 0.00	5.40		91.50(26.00)	26	91.50(26.00)	27	Lee (2003)
Ernest (2006)   47   81.84 (16.23)   32   88.23 (24.50)    11.31   -6.39   [-16.06, 3.28]     Subtotal (95% Cl)   258   232    100.00   -2.41   [-5.67, 0.84]     est for heterogeneity: Chi <sup>2</sup> = 1.40, df = 3 (P = 0.70), P = 0%     100.00   -2.41   [-5.67, 0.84]     est for overall effect: Z = 1.45 (P = 0.15)	6, 6.26]	0.00 [-6.26,	26.98 0.00	26.98	+	78.80(16.10)	52	78.80(16.80)	54	Lund (2005)
Subtolet (95% Cl) 2.58 2.32 • 100.00 -2.41 [-5.67, 0.84] fest for heterogeneity: Cl = 1.40, df = 3 (P = 0.70), P = 0% fest for overall effect: Z = 1.45 (P = 0.15)	06, 3.281	-6.39 [-16.06,	11.31 -6.39	11.31		88.23(24.50)	32	81.84(16.23)	47	Ernest (2006)
fest for heterogeneity: Chi² = 1.40, df = 3 (P = 0.70), i² = 0% fest for overall effect: Z = 1.45 (P = 0.15)	7, 0.841	-2.41 [-5.67,	100.00 -2.41	100.00	•		232		258	Subtotal (95% Cl)
fest for overall effect: Z = 1.45 (P = 0.15)								P = 0.70), I <sup>2</sup> = 0%	= 1.40, df = 3 (F	est for heterogeneity: Chi <sup>2</sup> =
									.45 (P = 0.15)	Test for overall effect: Z = 1.
				avours on pump	Favours off pump Favou					
-100 -50 0 50 100	2	0.00 [-6.3 -6.39 [-16 -2.41 [-5.6	26.98 0.00 11.31 -6.39 100.00 -2.41	26.98 11.31 100.00 50 100 avours on pump	-100 -50 0 Fayours off pump Fayou	78.80(16.10) 88.23(24.50)	52 32 232	78.80(16.80) 81.84(16.23) P = 0.70), I <sup>2</sup> = 0%	54 47 258 = 1.40, df = 3 (F .45 (P = 0.15)	Lund (2005) Ernest (2006) Subtotal (95% CI) Fest for heterogeneity: Chi <sup>2</sup> = Fest for overall effect: Z = 1.

Fig. 2. Meta-analysis of Grooved Pegboard test.

## 4. Discussion

Overall this systematic review has shown that there is no benefit in terms of neurocognitive outcomes in off-pump versus on-pump CABG. Of the five neurocognitive tests analysed, reflecting essentially four different domains, only one test showed any difference between groups. In that neurocognitive test of attention (Trail A), significant improvements were seen in the off-pump group at both

the early and late postoperative time points. However, the other test assessing the same general domain of attention and concentration (Trail B) showed no differences between groups at any time point. The discrepancy between these two tests can be explained on the basis of the different aspects of the domains they test. Trail A tests visual attention, with only a small element of scanning, eye-hand coordination and speed involved. Trail B is a much more complex task, incorporating the tasks of Trail A, and including the

Study or sub-category	N	Off pump Mean (SD)	N	On pump Mean (SD)		VVMD (fixed) 95% Cl	Weight %	VVMD (fixed) 95% Cl
01 Baseline								
Baker (2001)	12	38.83(13.55)	14	41.71(13.30)	←	•	- 10.98	-2.88 [-13.24, 7.48]
Zamvar (2002)	30	43.57(15.41)	30	40.37(14.22)	-		20.93	3.20 [-4.30, 10.70]
Lee (2003)	27	47.40(22.20)	26	43.70(32.60)	←		5.19	3.70 [-11.37, 18.77]
Ernest (2006)	61	42.64(14.96)	46	41.13(14.82)			- 36.33	1.51 [-4.19, 7.21]
Vedin (2006)	33	34.00(11.48)	37	37.00(16.72)			26.56	-3.00 [-9.66, 3.66]
Subtotal (95% CI)	163		153				100.00	0.30 [-3.14, 3.73]
Test for heterogeneity: Chi <sup>2</sup>	= 2.25, df = 4 (P	= 0.69), l <sup>2</sup> = 0%				T		
fest for overall effect: Z = 0	.17 (P = 0.87)	- Chower and The Contraction of						
02 Early neurocognitive state	us (less than 3 r	nonths)						
Baker (2001)	12	31.75(8.69)	14	40.71(19.40)	<b>+=</b>		3.71	-8.96 [-20.25, 2.33]
Zamvar (2002)	30	40.57(8.60)	30	38.74(13.00)	-		- 15.19	1.83 [-3.75, 7.41]
Lee (2003)	27	41.60(16.50)	26	42.80(33.10)	←	-	2.36	-1.20 [-15.36, 12.96]
Al-Ruzzeh (2006)	80	37.80(17.70)	79	43.80(14.30)	← ■		18.92	-6.00 [-11.00, -1.00]
Ernest (2006)	44	39.39(11.49)	41	39.00(17.58)			- 11.68	0.39 [-5.97, 6.75]
Vedin (2006)	31	29.00(5.56)	34	32.00(7.28)		<b></b>	48.14	-3.00 [-6.13, 0.13]
Subtotal (95% CI)	224		224		-		100.00	-2.62 [-4.79, -0.44]
Test for heterogeneity: Chi2	= 6.37, df = 5 (P	= 0.27), l <sup>2</sup> = 21.5%				-		
est for overall effect: Z = 2	2.36 (P = 0.02)							
03 Late neurocognitive statu	is (greater than	6 months)						
Baker (2001)	8	30.75(6.50)	10	40.90(11.41)	+		8.14	-10.15 [-18.53, -1.77]
Lee (2003)	27	45.70(15.20)	26	43.40(34.40)	←		2.75	2.30 [-12.11, 16.71]
Al-Ruzzeh (2006)	73	32.30(11.90)	72	40.20(12.80)	← ■		35.34	-7.90 [-11.92, -3.88]
Ernest (2006)	47	37.45(11.33)	32	41.69(15.42)	+ <b>-</b>		14.66	-4.24 [-10.49, 2.01]
Vedin (2006)	30	32.00(8.21)	32	34.00(7.07)		-	39.11	-2.00 [-5.83, 1.83]
Subtotal (95% CI)	185		172			•	100.00	-4.96 [-7.35, -2.57]
Test for heterogeneity: Chi <sup>2</sup>	= 6.85, df = 4 (P	= 0.14), l <sup>2</sup> = 41.6%			-			
Test for overall effect: Z = 4	.06 (P < 0.0001)							
	*********				-10 -5	0 5	10	***************************************
					Favours off	pump Favours on	pump	

Fig. 3. Meta-analysis of Trail A test.

alternating between letters and numbers (known as complex attention or set shifting). Set shifting is classified under the cognitive domain of executive function or frontal lobe function and is the basis for mental flexibility. Trail A tends to be a good indicator of general cerebral function and problems with this test indicate reduction in basic attention and speed of processing whereas Trail B is more specific to neuroanatomical areas. Thus it is not

Ol Baseline     12     86.17 (24.79)     14     115.50       Van Djk (2002)     142     83.00 (40.56)     139     84.00       Zamvar (2002)     30     98.30 (36.09)     30     94.33       Lec (2003)     29     126.00 (86.70)     29     114.90       Ernest (2006)     61     114.22 (56.87)     46     111.64       Vedin (2005)     33     82.00 (28.72)     37     104.00       Subtotal (55% Cl)     307     295     Test for heterogeneity: Chi <sup>2</sup> = 8.25, df = 5 (P = 0.14), I <sup>2</sup> = 39.4%     Test for overall effect: Z = 1.09 (P = 0.27)       U2 Early neurocognitive status (less than 3 months)     Baker (2001)     12     85.25 (24.68)     14     123.64       Van Djk (2002)     128     75.00 (33.33)     120     79.00       Zamvar (2001)     12     85.25 (24.68)     14     123.64       Van Djk (2002)     128     75.00 (33.33)     120     79.00       Zamvar (2002)     30     98.56 (19.50)     30     122.17     12.40       Lee (2003)     29     115.60 (52.30)     29	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$
Lee (2003)     29     126.00 (86.70)     29     114.90       Ernest (2006)     61     114.22 (86.87)     46     111.64       Vedin (2006)     33     82.00 (28.72)     37     104.00       Subtotil (95% Cl)     307     295     295       fest for heterogeneity: Chi <sup>2</sup> = 8 25, df = 5 (P = 0.14), P = 39.4%     295     295       fest for heterogeneity: Chi <sup>2</sup> = 8 25, df = 5 (P = 0.14), P = 39.4%     14     123.64       Van Dijk (2002)     12     85.25 (24.68)     14     123.64       Van Dijk (2002)     128     75.00 (33.93)     120     79.00       Zamvar (2002)     30     98.55 (19.90)     30     122.17       Lee (2003)     29     115.60 (52.30)     29     117.20       Al-Ruzzeh (2005)     44     97.25 (41.78)     31     100.97       Vedin (2005)     33     88.00 (16.70)     37     81.00       Subtotil (95% Cl)     356     340     340       set for heterogeneity: Chi <sup>2</sup> = 19.98, df = 6 (P = 0.003), I <sup>2</sup> = 70.0%     340	0(87.60)   2.32   11.10   [-33.76, 55.96]     14(45.01)   12.54   2.58   [-16.73, 21.89]     0(54.74)   11.48   -22.00   [-42.18, -1.82]     100.00   -3.81   [-10.65, 3.03]     10(33.93)   -   29.09   -4.00     0(104.50)   -   11.95   -23.61     0(104.50)   -   11.95   -23.61     0(134.60)   -   11.02   -4.00     0(134.57)   -   7.18   -3.71     0(14.57)   -   38.10   7.00   (-0.38, 14.38)
Ernest (2006)     61     114.22 (56.87)     46     111.64       Vedin (2006)     33     82.00 (28.72)     37     104.00       Subtotal (35% CI)     307     295     295       fest for heterogeneity: Chi <sup>2</sup> = 8.25, df = 5 (P = 0.14), P = 39.4%     295     295       vest for overall effect: Z = 1.09 (P = 0.27)     22     24     14     123.64       Van Dijk (2001)     12     85.25 (24.68)     14     123.64       Van Dijk (2002)     128     75.00 (33.93)     120     79.00       Zamvar (2002)     30     85.6 (19.90)     30     122.17       Lee (2003)     29     115.60 (52.30)     29     117.20       Al-Ruzzeh (2006)     80     111.40 (46.60)     79     115.40       Ernest (2005)     44     97.26 (41.78)     31     100.97       Vedin (2006)     33     88.00 (16.70)     37     81.00       Subtotal (95% CI)     356     340     340	12.54   2.58   [-16.73, 21.89]     11.45   -22.00   [-42.18, -1.82]     11.48   -22.00   [-42.18, -1.82]     100.00   -3.81   [-10.65, 3.03]     100.00   -3.81   [-10.65, 3.03]     100.00   -3.81   [-10.65, 3.03]     100.00   -3.81   [-10.73, 9.73]     100.00   -3.81   [-10.73, 9.73]     101.95   -23.61   [-36.79, -10.43]     101.95   -23.61   [-36.79, -10.43]     101.04   -11.95   -23.61     101.02   -4.00   [-17.73, 9.73]     101.02   -4.00   [-17.73, 9.73]     101.02   -4.00   [-10.73, 9.73]     101.02   -4.00   [-10.38, 14.38]     101.457)   -38.10   7.00     1000   -000   [-0.38, 14.38]
Vedin (2006)     33     82.00 (28.72)     37     104.00       Subtotil (35% CI)     307     295     295       rest for heterogeneity: Chi <sup>2</sup> = 8.25, df = 5 (P = 0.14), I <sup>2</sup> = 39.4%     295     295       rest for overall effect: Z = 1.09 (P = 0.27)     104.00     295       12 Early neurocognitive status (less than 3 months)     86.25 (24.66)     14     123.64       Van Dijk (2002)     128     75.00 (33.93)     120     79.00       Zamvar (2002)     30     98.55 (19.90)     30     122.17     12       Lee (2003)     29     115.60 (52.30)     29     117.20       Al-Ruzzeh (2006)     80     11.1.40 (46.60)     79     115.40       Ernest (2005)     44     97.25 (41.78)     31     100.97       Vedin (2006)     33     88.00 (16.70)     37     81.00       Subtotal (95% CI)     356     340     340	$\begin{array}{cccccccccccccccccccccccccccccccccccc$
Subtotal (95% CI)     307     295       Test for heterogeneity: Chi <sup>2</sup> = 8.25, df = 5 (P = 0.14), l <sup>2</sup> = 39.4%     5       Test for heterogeneity: Chi <sup>2</sup> = 8.25, df = 5 (P = 0.14), l <sup>2</sup> = 39.4%     5       22 Early neurocognitive status (less than 3 months)     Baker (2001)     12     85.25 (24.68)     14     123.64       Van Dijk (2002)     128     75.00 (33.93)     120     79.00       Zamvar (2002)     30     98.56 (19.90)     30     122.17       Al-Ruzzeh (2005)     29     115.60 (52.30)     29     117.20       Al-Ruzzeh (2005)     44     97.26 (41.78)     31     100.97       Vedin (2006)     33     88.00 (16.70)     37     81.00       Subtotid (55% CI)     356     340     54     57.26 (54.178)	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$
iest for heterogeneity: Chi <sup>2</sup> = 8.25, df = 5 (P = 0.14), P = 39.4%       iest for overall effect: Z = 1.09 (P = 0.27)       22 Early neurocognitive status (less than 3 months)       Baker (2001)     12     85.25 (24.68)     14     123.64       Van Dijk (2002)     128     75.00 (33.93)     120     79.00       Zamvar (2002)     30     98.56 (19.90)     30     122.17       Lee (2003)     29     115.60 (52.30)     29     117.20       Al-Ruzzeh (2006)     80     111.40 (46.60)     79     115.40       Ernest (2005)     44     97.26 (41.78)     31     100.97       Vedin (2006)     33     88.00 (16.70)     37     81.00       Stubtotal (95% CI)     356     340     340	$\begin{array}{cccccccccccccccccccccccccccccccccccc$
Test for overall effect:     Z = 1.09 (P = 0.27)       D2 Early neurocognitive status (less than 3 months)     Baker (2001)     12     85.25 (24.68)     14     123.64       Van Dijk (2002)     128     75.00 (33.93)     120     79.00       Zamvar (2002)     30     98.55 (19.90)     30     122.17       Lee (2003)     29     115.60 (52.30)     29     117.20       Al-Ruzzeh (2006)     80     111.40 (46.60)     79     115.40       Ernest (2005)     44     97.26 (41.78)     31     100.97       Vedin (2005)     33     88.00 (16.70)     37     81.00       Subtotal (95% CI)     356     340     545     546	$\begin{array}{cccccccccccccccccccccccccccccccccccc$
12 Early neurocognitive status (less than 3 months)       Baker (2001)     12     85.25 (24.68)     14     123.64       Van Dijk (2002)     128     75.00 (33.93)     120     79.00       Zamvar (2002)     30     98.55 (19.90)     30     122.17       Lee (2003)     29     115.60 (52.30)     29     117.20       Al-Ruzzeh (2006)     80     111.40 (46.60)     79     115.40       Ernest (2005)     44     97.25 (41.78)     31     100.97       Vedin (2006)     33     88.00 (16.70)     37     81.00       Stubtotal (95% CI)     356     340     340	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$
Baker (2001)     12     85.25 (24.66)     14     123.64       Van Dijk (2002)     128     75.00 (33.93)     120     79.00       Zamvar (2002)     30     98.55 (19.90)     30     122.17       Lee (2003)     29     115.60 (52.30)     29     117.20       Al-Ruzzeh (2005)     80     111.40 (46.60)     79     115.40       Ernest (2005)     44     97.25 (41.78)     31     100.97       Vedin (2005)     33     88.00 (16.70)     37     81.00       Subtotal (95% CI)     356     366     340     556 (19.90.003), I <sup>a</sup> = 70.0%	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$
Van Dijk (2002)     128     75.00 (33.93)     120     79.00       Zamvar (2002)     30     98.56 (19.90)     30     122.17       Lee (2003)     29     115.60 (52.30)     29     117.20       Al-Ruzzeh (2006)     80     111.40 (46.60)     79     117.20       Al-Ruzzeh (2006)     44     97.26 (41.78)     31     100.97       Vedin (2006)     33     88.00 (16.70)     37     81.00       Stubtotal (95% CI)     356     340     56     540	0(33.93) - 29.09 -4.00 [-12.45, 4.45]   7(31.00) - 11.95 -23.61 [-36.79, -10.42]   0(104.50) 1.15 -1.60 (-44.13, 40.93]   0(41.60) - 11.02 -4.00 [-17.73, 9.73]   7(33.22) 7.18 -3.71 [-20.71, 13.29]   0(14.57) 38.10 7.00 [-0.38, 14.38]
Zamvar (2002)     30     98.56 (19.90)     30     122.17       Lee (2003)     29     115.60 (52.30)     29     117.20       Al-Ruzzeh (2006)     80     111.40 (46.50)     79     115.40 (2006)       Ernest (2005)     44     97.26 (41.78)     31     100.97       Vedin (2006)     33     88.00 (16.70)     37     81.00       Stubtotal (95% CI)     356     340     340       est for heterogeneity: Chi² = 19.98, dif = 6 (P = 0.003), I² = 70.0%     340     340	7(31.00)  11.95 -23.61 [-36.79, -10.43]   9(104.50) 1.15 -1.60 [-44.13, 40.93]   9(41.60) 11.02 -4.00 [-17.73, 9.73]   9(33.22) 7.18 -3.71 [-20.71, 13.29]   9(14.57) 38.10 7.00 [-0.38, 14.38]
Lee (2003)     29     115.60 (\$2.30)     29     117.20       Al-Ruzzeh (2006)     80     111.40 (46.60)     79     115.40       Ernest (2006)     44     97.26 (41.78)     31     100.97       Vedin (2006)     33     88.00 (16.70)     37     81.00       Subtotal (95% CI)     356     340     340       Fest for heterogeneity: Chi² = 19.98, dif = 6 (P = 0.003), l² = 70.0%     500     500	0(104.50)   1.15   -1.60 [-44.13, 40.93]     0(41.60)   -   11.02   -4.00 [-17.73, 9.73]     0(32.22)   -   7.18   -3.71 [-20.71, 13.29]     0(14.57)   -   38.10   7.00 [-0.38, 14.38]
Al-Ruzzeh (2006)     80     111.40 (46.60)     79     115.40       Ernest (2006)     44     97.26 (41.78)     31     100.97       Vedin (2006)     33     88.00 (16.70)     37     81.00       Subtotal (95% Cl)     356     340     340       fest for heterogeneity: Chi <sup>2</sup> = 19.98, df = 6 (P = 0.003), I <sup>2</sup> = 70.0%     57.26     57.26	0(41.60) -4.00 [-17.73, 9.73]   7(33.22) 7.18   9(14.57) 38.10   7(00 [-0.38, 14.38]
Ernest (2005)     44     97.26 (41.78)     31     100.97       Vedin (2005)     33     88.00 (16.70)     37     81.00       Subtotal (95% CI)     356     340     340       set for heterogeneity. Chi² = 19.39, dif = 6 (P = 0.003), I² = 70.0%     570.0%     570.0%	7(33.22) 7.18 -3.71 (-20.71, 13.29)   0(14.57) 38.10 7.00 (-0.38, 14.38)
Vedin (2006) 33 88.00 (16.70) 37 81.00 \ubtotal (95% Cl) 356 340 est for heterogeneity: Chi² = 19.98, dir = 6 (P = 0.003), l² = 70.0%	)(14.57) <b>38.10</b> 7.00 [-0.38, 14.38]
Subtotal (95% Cl) 356 340 fest for heterogeneity: Chi <sup>2</sup> = 19.98, df = 6 (P = 0.003), l <sup>2</sup> = 70.0%	
est for heterogeneity: Chi <sup>2</sup> = 19.98, df = 6 (P = 0.003), l <sup>2</sup> = 70.0%	
est for overall effect: $z = 1.13$ (P = 0.26)	
3 Late neurocognitive status (greater than 6 months)	
Baker (2001) 8 84.75 (24.04) 10 107.30	0(70.58) 0.73 -22.55 [-69.36, 24.26]
Van Dijk (2002) 130 77.00 (35.88) 122 76.00	0(32.76) - 22.26 1.00 [-7.48, 9.48]
Lee (2003) 27 117.30 (63.40) 26 104.40	0(92.10) 0.88 12.90 [-29.82, 55.62]
Al-Ruzzeh (2006) 73 109.40(66.00) 72 102.40	4.81 7.00 [-11.24, 25.24]
Ernest (2006) 47 100.24 (45.42) 32 102.77	4.61 -2.53 [-21.15, 16.09]
Vedin (2006) 33 84.00 (9.58) 37 83.00	0(11.31) 66.72 1.00 (-3.90, 5.90)
Subtotal (95% Cl) 318 299	100.00 1.06 [-2.94, 5.06]
est for heterogeneity: Chi <sup>2</sup> = 1.82, df = 5 (P = 0.87), l <sup>2</sup> = 0%	

Fig. 4. Meta-analysis of Trail B test.

isation

Study or sub-category	N	Off pump Mean (SD)	N	On pump Mean (SD)	WMD (random) 95% Cl	Weight %	WMD (random) 95% Cl
01 Baseline						~~~~~	
Baker (2001)	12	-41.25(10.56)	14	-38.36(10.22)	<b>←</b>	6.44	-2.89 [-10.91, 5.13]
Van Dijk (2002)	142	-41.00(8.90)	139	-39.00(7.96)		31.30	-2.00 [-3.97, -0.03]
Zamvar (2002)	30	-42.47(10.23)	30	-42.80(18.19)		- 7.26	0.33 [-7.14, 7.80]
Lee (2003)	29	-45.30(17.00)	29	-52.50(17.00)		➡ 5.55	7.20 [-1.55, 15.95]
Lund (2005)	60	-36.60(8.90)	60	-36.40(9.60)		21.56	-0.20 [-3.51, 3.11]
Ernest (2006)	61	-49.03(12.28)	46	-45.93(12.82)		14.01	-3.10 [-7.92, 1.72]
Vedin (2006)	33	-40.00(10.05)	37	-36.00(10.64)		13.89	-4.00 [-8.85, 0.85]
Subtotal (95% CI)	367		355		-	100.00	-1.59 [-3.16, -0.01]
Test for heterogeneity: Cl Test for overall effect: Z	hi² = 6.40, df = 6 (P = 1.97 (P = 0.05)	<sup>9</sup> = 0.38), I <sup>2</sup> = 6.2%					
02 Early neurocognitive st	tatus (less than 3 i	months)					
Baker (2001)	1	0.00(0.00)	1	0.00(0.00)			Not estimable
Van Dijk (2002)	128	-45.00(9.00)	120	-42.00(7.10)		28.57	-3.00 [-5.01, -0.99]
Zamvar (2002)	30	-45.30(6.70)	30	-38.74(8.10)	<b>←−−−</b>	17.43	-6.56 [-10.32, -2.80]
Lee (2003)	29	-42.90(12.00)	29	-53.50(19.50)		5.56	10.60 [2.27, 18.93]
Lund (2005)	54	-38.90(10.40)	52	-38.80(9.70)		17.10	-0.10 [-3.93, 3.73]
Ernest (2006)	44	-51.68(13.43)	31	-48.71(14.10)		8.66	-2.97 [-9.32, 3.38]
Vedin (2006)	31	-42.00(6.95)	34	-41.00(4.37)		22.68	-1.00 [-3.85, 1.85]
Subtotal (95% CI)	317		297			100.00	-1.61 [-4.44, 1.22]
Test for heterogeneity: Ch	ni <sup>z</sup> = 16.71, df = 5 (	(P = 0.005), I <sup>2</sup> = 70.1%			-		
Test for overall effect: Z	= 1.11 (P = 0.27)						
03 Late neurocognitive st	atus (greater than	6 months)					
Van Dijk (2002)	130	-42.00(9.40)	122	-41.00(8.28)		33.67	-1.00 [-3.18, 1.18]
Lee (2003)	30	-43.70(14.50)	30	-53.80(22.10)		5.50	10.10 [0.64, 19.56]
Lund (2005)	54	-38.50(10.20)	52	-39.10(10.10)		20.85	0.60 [-3.26, 4.46]
Ernest (2006)	47	-52.30(13.96)	32	-49.94(12.46)		12.02	-2.36 [-8.24, 3.52]
Vedin (2006)	30	-42.00(4.10)	32	-39.00(7.07)		27.95	-3.00 [-5.86, -0.14]
Subtotal (95% CI)	291		268			100.00	-0.73 [-3.20, 1.73]
Test for heterogeneity: Ch Test for overall effect: Z	hi² = 8.01 , df = 4 (P = 0.59 (P = 0.56)	<sup>9</sup> = 0.09), l <sup>2</sup> = 50.1%					
		2 - 10 - <b>1</b> /10 - 10 - 10 - 10		50 B.C. B. 10	-10 -5 0 5	10	
					Favours off pump Favours on p	oump	

Fig. 5. Meta-analysis of Digit Symbol test.

uncommon to see a discrepancy between the two tests whereby the patient performs better in Trail A due to its more superficial assessment of attention, but performs worse in Trail B because of its more in-depth assessment of this cognitive domain. Further, the sample size in Trail A was smaller than Trail B although a post hoc sample size analysis showed that both tests had enough numbers to detect clinically significant differences (if we take the standard definition that a 20% decline is considered clinically significant).

Review

Comparison

Off pump vs on pump (Marasco)

01 Off pump vs on pump coronary revascularisation

The only other neurocognitive test which showed some difference between groups was the Digit Symbol test which assesses information processing speed. However, in that analysis the groups were not balanced at baseline, and there was also significant heterogeneity within groups. Re-analysis of the data for that test using a random effects model to account for the large amount of heterogeneity showed no significant differences between groups at any time point.

Our findings confirm the results of most of the individual trials included in the meta-analysis which showed only modest or no differences between groups. The studies by Baker et al. [25], Lund et al. [29], Ernest et al. [31], and Vedin et al. [32] were unable to show any significant differences between off-pump and on-pump CABG groups with neuro-cognitive testing. Zamvar et al. [26] found significantly worse neurocognitive outcomes in the on-pump CABG group using a definition of neurocognitive impairment as a deterioration of 1SD or more in two or more tests. Nine neuropsychometric tests were administered to all patients in that study of 60 patients. The two largest studies included in this meta-analysis both found some improvements in the off-pump groups [27,30]. The definition of neurocognitive decline is

crucial in these types of studies. Lee et al. [28] reported that, compared to baseline, off-pump CABG patients performed better on the Rey Auditory Verbal Learning Test at both the early and late follow-up times. However, when cognitive decline was defined as a 20% decline in 20% of the tests, then there was no difference between groups at either time frame.

The most recent prospective randomised trial on this topic by Motallebzadeh et al. [24] used a composite neurocognitive score to demonstrate better neurocognitive function in the off-pump group at the time of discharge but found no differences between groups at 6 weeks or 6 months postoperatively. We were able to include their unpublished data in our meta-analysis and found no difference in the overall results but a large increase in the heterogeneity. Due to publication restrictions on their unpublished data, we are unable to include it in the meta-analysis presented here.

The recommended core neuropsychological battery of tests lists the Rey Auditory Verbal Learning test, Trail A, Trail B, and the Grooved Pegboard test [8]. All of these tests were included in this meta-analysis. Thus the results reported here give a valid overall assessment of postoperative neurocognitive dysfunction.

One of the main discriminators in assessing the validity of meta-analyses is the degree of heterogeneity in the pooled results. Heterogeneity describes the level of variation in the individual trials. In these meta-analyses, there was no significant heterogeneity at baseline. Significant heterogeneity was seen mainly in the early outcomes (i.e. in the first 3 months postoperatively). This may be due to widely different times of testing within this 3-month window. The times of testing varied from 1 week to 3 months postoperatively in the

studies included. It has been suggested that testing during this timeframe is not meaningful because postoperative neurobehavioural dysfunction is highest in the immediate postoperative period and then declines [8]. This would largely account for the significant amount of heterogeneity seen in the results at this time period. Furthermore, a recent study of neurocognitive function after off-pump CABG has shown that older, anxious patients and those with new onset atrial fibrillation are more likely to have a worse neurocognitive score after surgery [33]. These types of confounding factors could also explain the level of heterogeneity seen, particularly in the early postoperative results.

The cognitive function of candidates for CABG has also been compared to healthy controls and published norms [34]. This has shown that preoperative patients with coronary artery disease have significantly reduced cognitive test scores compared to both healthy controls (matched by age, gender and education) and published norms. Again this may be due to anxiety or depression which has been suggested and refuted by a number of studies [34-36]. Other causative factors have been suggested such as the cardiac disease itself, or associated unrecognised cerebrovascular disease [37,38]. Because mood disturbance has been repeatedly associated with poor neurocognitive performance, concurrent assessment of mood has been recommended in the consensus statement on assessment of neurobehavioural outcomes after cardiac surgery [8]. Despite this, only four of the included studies reported performing a specific assessment of mood [28,30-32].

In general, all of the trials analysed for this meta-analysis were of good quality. However, it appears that in all but one of the studies, an aortic side-biting clamp was used in at least some patients in the off-pump group. This is disappointing as it is well known that manipulation of the aorta is associated with cerebral emboli, and therefore the purported benefits of offpump surgery (no aortic cannulation, no jet perfusion from the cannula tip, and no aortic cross-clamp) may have been lost [4]. None of the studies reported what percentage of patients had the side-biting clamp applied to the aorta so it is difficult to assess the magnitude of this as a confounding factor. Only one study specifically mentioned that the side-biting clamp was not used in the off-pump group [31]. Another study specifically mentioned that the side-biting clamp was used for every proximal anastomosis in the study which presumably refers to both the off-pump and on-pump groups [29].

Another confounding factor which should be taken into account in such studies is the effect of practice on the test results [39]. This can lead to the phenomenon of regression toward the mean whereby extreme baseline scores tend to become less extreme after repeated testing in the absence of any 'true' change. The statistical phenomenon of regression toward the mean has been found to adversely affect multiple different definitions of cognitive decline. In particular, definitions based on standard deviation (SD):postoperative decline in a subject's performance of more than 1SD of the group's scores before the operation; and the 20% method: decline of more than 20% of the subject's score before the operation, have been shown to be susceptible to this phenomenon [40]. Thus, it has been recommended that group mean scores be analysed as this allows the application of parametric statistical methods which are free from the influence of regression toward the mean. That is why we have followed this approach in this meta-analysis, using group mean data rather than analysing changes from baseline.

Other causes of improvements from baseline scores have been postulated however. It is conceivable that improvements could be a result of the coronary revascularisation, improved cardiac output and improved cerebral blood flow. However, it would be very difficult to demonstrate which of these phenomena would be more responsible for improvements in any particular study. Interestingly it has been shown that after one year postoperatively, cognitive function begins to decline again returning to preoperative levels at 5 years [41].

In terms of the post hoc sample size analysis we have performed, if we use the 20% decline in test result as a clinically significant cut-off, we can see that this meta-analysis has sufficient power to detect much smaller changes. On average, we had sufficient numbers to detect a 6% difference in test results with a power of 0.8 and type II error of <0.05.

In concluding that we have been unable to find any clinically relevant neurocognitive benefits to off-pump surgery, we have also assessed the clinical relevance of the limits of our confidence intervals. We have compared our results to published results of the minimum clinically important difference (MCID) [42]. This is defined as the smallest difference in result which can be perceived by the patient and is therefore clinically relevant. Unfortunately this score has not been published in a cohort of cardiac surgery patients to our knowledge. However, by comparing our confidence intervals to the published MCID for both the Grooved Pegboard and Digit Symbol tests in a group of epilepsy patients, we note that our confidence intervals lie well within the MCID for both of these tests.

There has been a recent move away from off-pump surgery because of lack of evidence of benefits. When offpump surgery was initially developed in 1990s, the proposed benefits were numerous. Interestingly the impetus for offpump surgery seemed to be largely driven by industry rather than the consumer. After an initially enthusiastic reception by surgeons, the lack of evidence substantiating these proposed benefits has tempered the use of this technique. Further, the patients who are most suitable for this type of surgery (single or double vessel disease) are referred less and less by cardiologists because these patients are also eminently suitable for stenting and other percutaneous interventional techniques.

Other reviews have looked at other endpoints comparing off-pump to on-pump CABGs and found few significant differences. A recent scientific statement from the American Heart Association reports that the current findings consistently favouring off-pump CABG surgery are less bleeding and fewer requirements for blood transfusion. There is little evidence of other significant benefits. In contrast, on-pump CABG is less technically demanding and has a shorter learning curve [43]. That statement was published in 2005 and at that time there was no systematic review based on randomised trials to show a substantial stroke reduction in off-pump versus on-pump CABG.

However, in 2006 a meta-analysis looking at stroke as the main endpoint was published which showed that off-pump

CABG is associated with a 50% reduction in the relative risk of stroke (RR 0.50; 95% CI, 0.27–0.93) [5]. Stroke was reported in 27 trials and evaluated in 3062 patients. That paper also found a 30% reduction in atrial fibrillation (RR 0.70; 95% CI, 0.57–0.84) and a 48% reduction in wound infection (RR 0.52; 95% CI, 0.37–0.74).

A meta-analysis looking specifically at cognitive decline after off-pump versus on-pump CABG was published during the preparation of this manuscript. Interestingly they did not include two RCTs we have included in this manuscript with unpublished data from the authors [44]. Two papers they did include however, we chose to exclude due to failure to conform to the consensus statement of cognitive testing after CABG [10] and reporting of cognitive outcomes as the number of deteriorations per group (susceptible to regression toward the mean) without reporting group means [11]. (We were unable to obtain raw data from the last author). Despite the less rigorous inclusion criteria, the meta-analysis by Tagaki et al. also failed to find any significant differences between groups within 2 weeks or at 6–12 months.

In conclusion, this meta-analysis comparing neurocognitive outcomes between patients undergoing off-pump versus on-pump CABGs has found that there is no clinically relevant difference between groups either early (less than 3 months) or late (6-12 months) after surgery. Future studies examining this outcome should aim to employ a technique of no aortic handling at all to minimise confounding factors. Neurocognitive testing and reporting of results should follow the guidelines suggested by the consensus statement, and detailed data should be included in publications rather than summarised data [8]. A multicentre prospective randomised clinical trial is currently underway aiming to enrol 2200 patients into either off-pump or on-pump arms [45]. The secondary outcomes in that trial include neurocognitive testing at baseline and at one year. If follow-up rates are good, this trial will hopefully add important data to our current knowledge of neurocognitive outcomes after offpump CABG.

# Acknowledgements

The authors thank Dr Christine Ernest and Dr Barbara Murphy for providing data from their study for inclusion in this analysis, and for advice on the neurocognitive test results. The authors also thank Hoang Nguyen for his assistance with the initial compilation of data and to Michael Bailey PhD, MSc (statistics), for his assistance with the post hoc sample size analysis.

No funding was sought for this study.

## References

- [1] Tatoulis J, Rice S, David P, Goldblatt JC, Marasco S. Patterns of postoperative systemic vascular resistance in a randomized trial of conventional on-pump versus off-pump coronary artery bypass graft surgery. Ann Thorac Surg 2006;82(4):1436–44.
- [2] Paparella D, Galeone A, Venneri MT, Coviello M, Scrascia G, Marraudino N, Quaranta M, de Luca Tupputi Schinosa L, Brister SJ. Activation of the coagulation system during coronary artery bypass grafting: comparison between on-pump and off-pump techniques. J Thorac Cardiovasc Surg 2006;132(3):733-4.

- [3] Brown WR, Moody DM, Challa VR, Stump DA, Hammon JW. Longer duration of cardiopulmonary bypass is associated with greater numbers of cerebral microemboli. Stroke 2000;31:707–13.
- [4] Abu-Omar Y, Balacumaraswami L, Pigott DW, Matthews PM, Taggart DP. Solid and gaseous cerebral microembolization during off-pump, on-pump, and open cardiac surgery procedures. J Thorac Cardiovasc Surg 2004;127:1759–65.
- [5] Sedrakyan A, Wu AW, Parashar A, Bass EB, Treasure T. Off-pump surgery is associated with reduced occurrence of stroke and other morbidity as compared with traditional coronary artery bypass grafting: a metaanalysis of systematically reviewed trials. Stroke 2006;37(11):2759–69.
- [6] Palmer G, Herbert MA, Prince SL, Williams JL, Magee MJ, Brown P, Katz M, Mack MJ. Coronary artery revascularization (CARE) Registry: an observational study of on-pump and off-pump coronary artery revascularization. Ann Thorac Surg 2007;83:986–92.
- [7] Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Lancet 1999;354:1896–9.
- [8] Murkin JM, Newman SP, Stump DA, Blumenthal JA. Statement of consensus on assessment of neurobehavioral outcomes after cardiac surgery. Ann Thorac Surg 1995;59:1289–95.
- [9] Westaby S, Saatvedt K, White S, Katsumata T, van Oeveren W, Bhatnagar NK, Brown S, Halligan PW. Is there a relationship between serum S-100β protein and neuropsychologic dysfunction after cardiopulmonary bypass? J Thorac Cardiovasc Surg 2000;119:132–7.
- [10] Diegeler A, Hirsch R, Schneider F, Schilling LO, Falk V, Rauch T, Mohr FW. Neuromonitoring and neurocognitive outcome in off-pump versus conventional coronary bypass operation. Ann Thorac Surg 2000;69(4):1162– 6.
- [11] Lloyd CT, Ascione R, Underwood MJ, Gardner F, Black A, Angelini GD. Serum S-100 protein release and neuropsychological outcome during coronary revascularization on the beating heart: a prospective randomized study. J Thorac Cardiovasc Surg 2000;119:148–54.
- [12] Lund C, Hol PK, Lundblad R, Fosse E, Sundet K, Tennoe B, Brucher R, Russell D. Comparison of cerebral embolization during off-pump and onpump coronary artery bypass surgery. Ann Thorac Surg 2003;76:765–70.
- [13] Schmitz C, Weinreich S, Schneider R, Schneider D, Speth I, Schulze-Rauschenbach C, Pohl C, Welz A. Off-pump versus on-pump coronary artery bypass: Can OPCAB reduce neurological injury? Heart Surg Forum 2003;6(3):127–9.
- [14] Keizer AMA, Hijman R, van Dijk D, Kalkman CJ, Kahn RS. Cognitive selfassessment one year after on-pump and off-pump coronary artery bypass grafting. Ann Thorac Surg 2003;75:835–9.
- [15] van Dijk D, Moons KGM, Keizer AMA, Jansen EWL, Hijmna R, Diephius JC, Borst C, de Jaegere PPT, Grobbee DE, Kalkman CJ. Association between early and 3 month cognitive outcome after off-pump and on-pump coronary bypass surgery. Heart 2004;90:431–4.
- [16] Ascione R, Ghosh A, Reeves BC, Arnold J, Potts M, Shah A, Angelini GD. Retinal and cerebral microembolization during coronary artery bypass surgery. A randomized, controlled trial. Circulation 2005;112:3833–8.
- [17] Stroobant N, Van Nooten G, Van Belleghem Y, Vingerhoets G. Relation between neurocognitive impairment, embolic load, and cerebrovascular reactivity following on- and off-pump coronary artery bypass grafting. Chest 2005;127(6):1967–76.
- [18] Kobayashi J, Tashiro T, Ochi M, Yaku H, Watanabe G, Satoh T, Tagusari O, Nakajima H, Kitamura S. Early outcome of a randomized comparison of off-pump and on-pump multiple arterial coronary revascularization. Circulation 2005;112(Suppl. 1):I338–43.
- [19] Diephuis JC, Moons KGM, Nierich AN, Bruens M, van Dijk D, Kalkman CJ. Jugular bulb desaturation during coronary artery surgery: a comparison of off-pump and on-pump procedures. Br J Anaesth 2005;94:715–20.
- [20] Jensen BO, Hughes P, Rasmussen LS, Pedersen PU, Steinbruchel DA. Cognitive outcomes in elderly high-risk patients after off-pump versus conventional coronary artery bypass grafting. A randomized trial. Circulation 2006;113:2790-5.
- [21] Chernov VI, Efimova NY, Efimova IY, Akhmedov SD, Lishmanov YB. Shortterm and long-term cognitive function and cerebral perfusion in off-pump and on-pump coronary artery bypass patients. Eur J Cardiothorac Surg 2006;29:74–81.
- [22] Bonacchi M, Prifti E, Maiani M, Bartolozzi F, Di Eusanio M, LEacche M. Does off-pump coronary revascularization reduce the release of the cerebral markers S-100β and NSE? Heart Lung Circ 2006;15:314–9.
- [23] Biancari F, Mosorin M, Rainaho E, Lahtinen J, Heikkinen J, Niemela E, Anttila V, Lepojärvi M, Juvonen T. Postoperative stroke after off-pump

versus on-pump coronary artery bypass surgery. J Thorac Cardiovasc Surg 2007;133(1):169–73.

- [24] Motallebzadeh R, Bland JM, Markus HS, Kaski JC, Jahangiri M. Neurocognitive function and cerebral emboli: randomized study of on-pump versus off-pump coronary artery bypass surgery. Ann Thorac Surg 2007; 83(2):475–82.
- [25] Baker RA, Andrew MJ, Ross IK, Knight JL. The Octopus II stabilizing system: biochemical and neuropsychological outcomes in coronary artery bypass surgery. Heart Surg Forum 2001;4(Suppl. 1):S19–23.
- [26] Zamvar V, Williams D, Hall J, Payne N, Cann C, Young K, Karthikeyan S, Dunne J. Assessment of neurocognitive impairment after off-pump and on-pump techniques for coronary artery bypass graft surgery: prospective randomised controlled trial. BMJ 2002;325(7375):1268.
- [27] van Dijk D, Jansen EWL, Hijman R, Nierich AP, Diephuis JC, Moons KGM, Lahpor JR, Borst C, Keizer AMA, Grobbee DE, de Jaegere PP, Kalkman CJ. Cognitive outcome after off-pump and on-pump coronary artery bypass graft surgery: a randomized trial. JAMA 2002;287:1405–12.
- [28] Lee JD, Lee SJ, Tsushima WT, Yamauchi H, Lau WT, Popper J, Stein A, Johnson D, Lee D, Petrovitch H, Dang CR. Benefits of off-pump bypass on neurologic and clinical morbidity: a prospective randomized trial. Ann Thorac Surg 2003;76(1):18–25.
- [29] Lund C, Sundet K, Tennoe B, Hol PK, Rein KA, Fosse E, Russell D. Cerebral ischemic injury and cognitive impairment after off-pump and on-pump coronary artery bypass grafting surgery. Ann Thorac Surg 2005;80: 2126–31.
- [30] Al-Ruzzeh S, George S, Bustami M, Wray J, Ilsley C, Athanasiou T, Amrani M. Effect of off-pump coronary artery bypass surgery on clinical, angiographic, neurocognitive, and quality of life outcomes: randomised controlled trial. BMJ 2006;332(7554):1365.
- [31] Ernest CS, Worcester MU, Tatoulis J, Elliott PC, Murphy BM, Higgins RO, Le Grande MR, Goble AJ. Neurocognitive outcomes in off-pump versus onpump bypass surgery: a randomized controlled trial. Ann Thorac Surg 2006;81(6):2105–14.
- [32] Vedin J, Nyman H, Ericsson A, Hylander S, Vaage J. Cognitive function after on or off pump coronary artery bypass grafting 2006;30:305–10.
- [33] Sendelbach S, Lindquist R, Watanuki S, Savik K. Correlates of neurocognitive function of patients after off-pump coronary artery bypass surgery. Am J Crit Care 2006;15(3):290–8.
- [34] Ernest CS, Murphy BM, Worcester MUC, Higgins RO, Elliott PC, Goble AJ, Le Grande MR, Genardini N, Tatoulis J. Cognitive function in candidates for coronary artery bypass graft surgery. Ann Thorac Surg 2006;82:812–8.

- [35] Keith JR, Puente AE, Malcolmson KL, Coleman AE, Marks Jr HF. Assessing postoperative cognitive change after cardiopulmonary bypass surgery. Neurospychology 2002;16:411–21.
- [36] Vingerhoets G, Van Nooten G, Jannes C. Neuropsychological impairment in candidates for cardiac surgery. J Int Neuropsychol Soc 1997;3:480–4.
- [37] Rosengart TK, Sweet J, Finnin EB, Wolfe P, Cashy J, Hahn E, Marymont J, Sanborn T. Neurocognitive functioning in patients undergoing coronary artery bypass graft surgery of percutaneous coronary intervention: evidence of impairment before intervention compared with normal controls. Ann Thorac Surg 2005;80:1327–35.
- [38] Waldstein SR, Snow J, Muldoon MF, Katzel LI. Neuropsychological consequences of cardiovascular disease. In: Tarter RE, Butters M, Beers SR, editors. Medical neuropsychology. 2nd ed., New York, NY: Kluwer Academic Plenum; 2001. p. 51–83.
- [39] Byrne DG. Neuropsychological dysfunction and assessment of patients following cardiac arrest, myocardial infarction and major cardiac surgery. In: Touyz S, Byrne D, Gilandas A, editors. Neuropsychology in clinical practice. Sydney: Academic Press/Harcourt Brace; 1994. p. 286–304.
- [40] Browne SM, Halligan PW, Wade DT, Taggart DP. Cognitive performance after cardiac operation: implications of regression toward the mean. J Thorac Cardiovasc Surg 1999;117:481–5.
- [41] Selnes OA, Royall RM, Grega MA, Borowicz LM, Quaskey S, McKhann GM. Cognitive changes 5 years after coronary artery bypass grafting. Is there evidence of late decline? Arch Neurol 2001;58:598–604.
- [42] Blum D, Meador K, Biton V, Fakhoury T, Shneker B, Chung S, Mills K, Hammer A, Isojarvi J. Cognitive effects of lamotrigine compared with topiramate in patients with epilepsy. Neurology 2006;67:400–6.
- [43] Sellke FW, DiMaio JM, Caplan LR, Ferguson TB, Gardner TJ, Hiratzka LF, Isselbacher EM, Lytle BW, Mack MJ, Murkin JM, Robbins RC. Comparing onpump and off-pump coronary artery bypass grafting: numerous studies but few conclusions: a scientific statement from the American Heart Association council on cardiovascular surgery and anesthesia in collaboration with the interdisciplinary working group on quality of care and outcomes research. Circulation 2005;111(21):2858–64.
- [44] Takagi H, Tanabashi T, Kawai N, Umemoto T. Cognitive decline after offpump versus on-pump coronary artery bypass graft surgery: Meta-analysis of randomized controlled trials. J Thorac Cardiovasc Surg 2007;134:512–3.
- [45] Novtzky D, Shroyer AL, Collins JF, McDonald GO, Lucke J, Hattler B, Kozora E, Bradham DD, Baltz J, Grover FL. A study design to assess the safety and efficacy of on-pump versus off-pump coronary bypass grafting: the ROOBY trial. Clin Trials 2007;4:81–91.